Company news
Arcturus Therapeutics Holdings Inc. news in 2022
Arcturus Therapeutics Holdings Inc.'s news releases, calls and decks from 2022, newest first.
Arcturus Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference
December 18, 2022
Arcturus Appoints John Markels, Ph.D. to its Board of Directors
December 12, 2022
Arcturus Therapeutics Announces Third Quarter 2022 Financial Update and Pipeline Progress
November 8, 2022
Arcturus Therapeutics to Present at the Following Investor Conferences in November
November 6, 2022
Arcturus Announces Collaboration with CSL to Develop and Commercialize Self-amplifying mRNA Vaccines
October 31, 2022
Arcturus Therapeutics to Report Third Quarter 2022 Financial Results and Provide Corporate Update on November 9, 2022
October 25, 2022
Arcturus Therapeutics to Attend the Following Investor Conferences
September 26, 2022
Arcturus Announces $63.2 Million Award from the U.S. Government to Support Development of Self-amplifying mRNA Vaccine for Rapid Pandemic Influenza Response
August 30, 2022
Arcturus Reports Durability Data Against Omicron Variants, Including BA.5, at Six-Month Timepoint Following Booster with ARCT-154 COVID-19 Vaccine
August 17, 2022
Arcturus Therapeutics Announces Second Quarter 2022 Financial Update and Pipeline Progress
August 8, 2022
Arcturus Therapeutics to Report Second Quarter 2022 Financial Results and Provide Corporate Update on August 9, 2022
July 31, 2022
Arcturus Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
June 20, 2022
Arcturus Therapeutics Announces First Quarter 2022 Financial Update and Pipeline Progress
May 8, 2022
CORRECTING and REPLACING GRAPHIC Arcturus Reports Strong Three-Month Durability Results from ARCT-154 Booster Trial
May 4, 2022
Arcturus Therapeutics to Report First Quarter 2022 Financial Results and Provide Corporate Update on May 9, 2022
April 26, 2022
Arcturus Announces Self-amplifying COVID-19 mRNA Vaccine Candidate ARCT-154 Meets Primary Efficacy Endpoint in Phase 3 Study
April 19, 2022
Arcturus Therapeutics to Participate in the Cantor Fitzgerald Virtual Rare Orphan Disease Summit
March 24, 2022
Arcturus Therapeutics to Participate in the Barclays Global Healthcare Conference
March 13, 2022
Arcturus Therapeutics Announces Fourth Quarter and Full Year 2021 Financial Update and Pipeline Progress
February 27, 2022
Arcturus Therapeutics to Report Fourth Quarter and Year-End 2021 Financial Results and Provide Corporate Update on February 28, 2022
February 15, 2022
Arcturus Therapeutics to Participate in the SVB Leerink 11th Annual Global Healthcare Conference
February 7, 2022
Arcturus Therapeutics Reports New Data Demonstrating Neutralizing Antibody Immune Response to the SARS-CoV-2 Omicron Variant from ARCT-154 and ARCT-165 Booster Clinical Trial
January 24, 2022
Arcturus Therapeutics Updates Data from ARCT-154 and ARCT-165 Booster Clinical Trial Demonstrating Robust Neutralizing Antibody Responses to SARS-CoV-2 and Several Variants
January 23, 2022
Calls in 2022
- Arcturus Therapeutics Holdings (NASDAQ:ARCT) Q3 2022 Earnings Call
Nov 9, 2022
Transcript - Arcturus Therapeutics Holdings (NASDAQ:ARCT) Q2 2022 Earnings Call
Aug 9, 2022
Transcript - Arcturus Therapeutics Holdings (NASDAQ:ARCT) Q1 2022 Earnings Call
May 9, 2022
Transcript - Arcturus Therapeutics Holdings (NASDAQ:ARCT) Q4 2021 Earnings Call
Feb 28, 2022
Transcript
Decks in 2022
- 45th European Cystic Fibrosis Conference (ECFC) 2022, Rotterdam, Workshop 16
Conference · 10 slides · Jun 10, 2022
- Investor Presentation (February 2022)
Investor deck · 48 slides · Feb 17, 2022